the process of implantation, trophoblast invasion and placentation demand continuous adaptation and modifications between the trophoblast (embryonic) and the decidua (maternal). Within the decidua, the maternal immune system undergoes continued changes, as the pregnancy progress, in terms of the cell population, phenotype and production of immune factors, cytokines and chemokines. Human chorionic gonadotropin (hCG) is one of the earliest hormones produced by the blastocyst and has potent immune modulatory effects, especially in relation to T cells. We hypothesized that trophoblastderived hcG modulates the immune population present at the maternal fetal interface by modifying the cytokine profile produced by the stromal/decidual cells. Using in vitro models from decidual samples we demonstrate that hcG inhibits CXCL10 expression by inducing H3K27me3 histone methylation, which binds to Region 4 of the CXCL10 promoter, thereby suppressing its expression. hCG-induced histone methylation is mediated through EZH2, a functional member of the PRC2 complex. Regulation of CXCL10 expression has a major impact on the capacity of endometrial stromal cells to recruit CD8 cells. We demonstrate the existence of a cross talk between the placenta (hCG) and the decidua (CXCL10) in the control of immune cell recruitment. Alterations in this immune regulatory function, such as during infection, will have detrimental effects on the success of the pregnancy.
DCs during the preimplantation period 13 . Human endometrial stromal cells (HESCs) are known to produce and secrete various chemokines, including Interleukin-8 (IL-8) 14, 15 , growth-regulated oncogene (GRO) α [16] [17] [18] , monocyte chemoattractant protein-1 (MCP-1) 15, 19 , macrophage inflammatory protein-1 (MIP-1α) 20 , regulated upon activation normal T cell expressed and secreted (RANTES) 21, 22 and interferon-induced protein 10 (IP-10) 23 . The expression of these cytokines has been suggested to be important in menstruation, infections (bacterial and viral), implantation and in the support of early pregnancy 24, 25 . Interestingly, the maintenance of pregnancy requires the inhibition of many of these cytokines/chemokines in order to restrict the recruitment of immune cells, such cytotoxic CD8 T cells that could endanger the acceptance of the fetus. Furthermore, several reports suggest that during pregnancy, the decidua is responsible for actively restricting access of cytotoxic CD8 T cells to the maternal-fetal interface 26 suggesting that the process of differentiation from endometrial stromal cells into decidual cells involves the existence of active mechanisms regulating chemokine expression and function.
Human and animal studies have demonstrated that the cytokine milieu in the uterus is not only different between the pregnant and non-pregnant uterus, but it differs between early and late pregnancy 6, 27, 28 . Indeed, implantation and early trophoblast invasion have been shown to depend on the presence of inflammatory signals necessary for the attachment of the embryo to the surface epithelium of the uterus 29 . However, once implantation is achieved, the inflammatory environment needs to be reversed into an anti-inflammatory state in order to prevent maternal rejection of the embryo 30, 31 . The signals regulating this shift at the implantation site have not yet been defined.
Human chorionic gonadotropin (hCG) is one of the earliest hormones produced by the blastocyst and has potent immune modulatory effects, especially in relation to T cells [32] [33] [34] , B cells and dendritic cells 35, 36 . hCG has been suggested to induce the immune modulatory changes in the phenotype and function of immune cells by either a direct pathway that involves the direct binding of hCG to its receptor on T and B cells 34, 37 , or indirect pathways by inducing changes in regulatory cell populations such as dendritic cells [38] [39] [40] or decidual/stromal cells. The interaction between hCG and stromal cell differentiation and immune regulatory function is unknown.
Several of the modifications taking place in the uterus in preparation for and during pregnancy are epigenetic modifications in response to local and systemic signals. The Polycomb-group (PcG) proteins make up the two Polycomb repressor complexes, PRC1 and PRC2 41 and are major regulators of cell differentiation. Each complex is composed of known core proteins, which represent the evolutionary conserved components of the complex [42] [43] [44] [45] . Fine-tuning of the different components of each PRC has been observed in different cell types and in different cellular states 46 . In humans, PRC1 is composed of core proteins Bmi-1/Mel-18, CBX, RING1, and PHC while PRC2 is composed of EZH2, EED, and SUZ12. Multiple isoforms exist for each PcG protein and therefore, depending on the cell type and cellular state, the components of each PRC vary. PRCs suppress gene transcription through binding to the chromatin at the polycomb responsive elements (PRE) and promoting methylation [47] [48] [49] . EZH2 provides the methyltransferase activity on histone lysine residues that is essential for inducing transcriptional repression and stable gene silencing. Although it has been shown that the PcG proteins play an important role in the differentiation and function of decidual cells, the factors controlling these epigenetic modifications have not been elucidated. Previously, Nancy et al. 50 reported in mice that CXCL9 and CXCL10, two important chemokines, are transcriptionally silenced during decidualization in the mouse uterus. This happened in association with promoter addition of tri-methyl histone H3 lysine 27 (H3K27me3), a repressive histone mark generated by polycomb repressive complex 2 (PRC2). H3K27me3 is an epigenetic modification to the DNA packaging protein Histone H3 and constitutes a mark that indicates the tri-methylation to the 27th lysine residue of the histone H3 protein. This tri-methylation is associated with the downregulation of nearby genes via the formation of heterochromatic regions 51 .
The objective of this study was to characterize the mechanisms associated with the regulation of the chemokine CXCL10 expression during the process of stromal-decidual differentiation. We tested the hypothesis that the trophoblast signal hCG, is responsible for the suppression of pro-inflammatory cytokines, specifically CXCL10 expression by uterine stromal cells by regulating H3K27me3 histone modifications. We report the identification of a specific site at the promoter region of CXCL10 modified by H3K27me3 and show that hCG-induced H3K27me3 modification requires the recruitment of the PRC2 member EZH2. Furthermore, we describe the clinical correlation between circulating hCG and CXCL10 levels during early gestation in normal pregnancies.
Results
Decidual stromal cells (DSCs) secrete a specific cytokine profile that results in decreased CD8 T cell migration compared to stromal cells. Our first objective was to determine the capacity of human endometrial stromal cells versus decidual cells to recruit immune cells and to characterize their chemokine profile. To achieve this objective, we used an in vitro model consisting of a telomerase immortalized human endometrial stromal cell line (HESCs) which can undergo in vitro differentiation into decidual cells (DSCs) by continued treatment with estrogen, progesterone and cAMP as previously reported and described in the Material and Methods 52 . In short, HESCs were exposed to estrogen, progesterone and cAMP for 5-9 days and the differentiation of HESCs into DSCs was confirmed by morphologic changes such as enlarged, rounded morphology compared to the elongated spindle-shaped fibroblastic stromal cells ( Fig. 1A ) and the increased expression of Prolactin and IGFBP-1 (Fig. 1B) 52 . Afterwards, we evaluated the capacity of these cells to recruit immune cells by using a 5 µM trans-well two-chamber migration assay where conditioned media (CM) collected from HESCs or DSCs (see M&M for preparation of CM) were added to the bottom chamber as chemoattractant and peripheral blood mononuclear cells (PBMCs) (350,000 cells/well) were added to the upper chamber. After 24 h, all the cells that migrated into the lower chamber were collected and the number of T cells (CD4 and CD8) was evaluated by flow cytometry. We observed a significantly higher number of T cells present in the chambers containing HESCs' CM (18,543 ± 115 T cells) compared to the chambers containing CM from DSCs (10,007 ± 1654 T cells) www.nature.com/scientificreports www.nature.com/scientificreports/ (p < 0.05) (Fig. 2B ). The proportion of recruited CD4 and CD8 T cells were significantly reduced in the chambers containing CM from DSCs compared to the chambers containing HESCs' CM ( Fig. 2A,C) These findings suggest that HESCs are highly effective in recruiting T cells; however, differentiation into DSCs is associated with a significant drop in their recruitment capacity.
Cytokines and chemokines are the main mediators of immune cell recruitment; consequently, we evaluated, using Luminex analysis, whether there were differences in the cytokine and chemokine profile between HESC and DSCs that could explain the observed differential capacity to recruit T cells between these two cell types. Table 1 summarizes the cytokine/chemokine profile from supernatants obtained from these two cell types. HESCs are characterized by the secretion of pro-inflammatory cytokines, IL6, IL-12, IL-17, IFN-γ and chemokines IL-8, G-CSF CXCL-10, MIP-1α, VEGF and CCL5 (RANTES) ( Table 1) ; however, upon differentiation into DSC cells, we observed a significant reduction in the secretion levels of these pro-inflammatory cytokines and chemokines ( Table 1) .
CXCL10 is a potent chemoattractant for CD8 + T cells and is highly expressed in the supernatant of HESCs but its expression is dampened upon differentiation into DSC; hence, we hypothesized that the decrease in migration of CD8 + T cells with the DSCs CM might be due to the inhibition of CXCL10 expression after decidualization. Accordingly, we sought to elucidate the potential mechanisms responsible for the regulation of CXCL10 expression in HESCs/DSCs and its impact on T cell recruitment. hCG/cyclic AMP pathway regulates CXCL10 expression during cellular differentiation. In order to determine whether the process of differentiation from stromal cells into decidua cells is associated with the changes on CXCL10 expression, we evaluated CXCL10 mRNA levels in HESCs before and after differentiation into DSCs. Similar to the findings with the secreted protein, the process of decidualization is associated with transcriptional inhibition of CXCL10, demonstrated by decreased levels of CXCL10 mRNA in DSCs, which correlated with lower levels of secreted protein expression compared to the HESCs (Fig. 3A,B ). Since estrogen and progesterone are known to be the main hormones involved in the process of decidual differentiation; we first tested the effect of either estrogen or progesterone on CXCL10 expression by stromal cells. Interestingly, neither estrogen nor progesterone were responsible for the modulatory effect on CXCL10 expression levels during decidualization ( Fig. 3C ). However, we did observe a significant inhibitory effect on CXCL10 mRNA and protein expression following cAMP treatment, the other major mediator of decidualization 53 (Fig. 3A -C); suggesting that factors that could activate cAMP might have modulatory effects on CXCL10 expression.
hCG is one of the early factors secreted by the trophoblast and is known to have immune modulatory effects during pregnancy, especially with regards to the recruitment of regulatory T and B cells 33, 34 . The cellular effects of hCG are mediated through the LH receptor (LHR), a G-protein coupled receptor, and ligation of the receptor results in an increase in intracellular cAMP, its secondary messenger whose resulting protein cascades affect target gene expression 54 . Therefore, we hypothesize that hCG, though the induction of cAMP could inhibit recruitment of CD8 + T cells by suppressing CXCL10 expression in endometrial stromal cells. To test this hypothesis, we first evaluated the overall effect of hCG on cytokine/chemokine expression by HESCs. As shown in Table 1 , column 3, hCG treatment had a notable inhibitory effect on HESCs' cytokine and chemokine expression profile, similar to the one observed with the process of differentiation into decidual cells (Table 1) .
Next, we characterized the potential transcriptional regulatory role of hCG on HESC's CXCL10 expression by treating HESCs with hCG and determining CXCL10 mRNA expression. As shown in Fig. 4 , HESCs treated with hCG revealed decreased CXCL10 mRNA expression ( Fig. 4A ) and this effect was dose and time dependent, further supporting the specificity of its effect ( Fig. 4B,C) . The inhibitory effect observed with hCG resembles the one determined with cAMP ( Fig. 3 ).
hCG/cyclic AMP pathway is an epigenetic regulator of CXCL10 expression by inducing histone methylation.
Epigenetic modifications, such as histone methylation, play a central role in the regulation of cytokines and chemokines expression 55 ; therefore, we hypothesized that the hCG/cAMP pathway may silence the promoter of CXCL10 (the human gene that codes for CXCL10) by histone methylation. As indicated above, H3K27me3 modification is associated with gene shutting down target gene transcription 56, 57 . First, we determined whether the hCG/cAMP pathway could affect global H3K27 methylation by treating HESCs with hCG or cAMP for 2 h and evaluating H3K27me3 modification by western blot analysis. As shown in Fig. 5A , HESCs cells treated with either hCG or cyclic AMP showed increased levels of H3K27me3 modification when compared to non-treated cells ( Fig. 5A,B ). Furthermore, when we expose HESCs to increasing concentrations of hCG, we observed a dose dependent increase on H3K27me3 modification ( Fig. 5C ,D). Total H3 was not affected by any of these treatments, confirming that the effect is associated with increasing methylation of H3K27 ( Fig. 5A-D) . Next, we sought to determine the molecular mechanism of how hCG mediates H3K27me3 modification. The PRC2 complex is the main regulator of H3K27me3 modification through the specific histone methyltransferase, EZH2. EZH2 catalyzes the methylation of Histone 3 at Lysine 27 (K27) 45 . Hence, we evaluated EZH2 in the regulation of H3K27me3 in HESC by using an inhibitor for EZH2, GSK126. Thus, DSCs, which express high levels of H3K27me3 and low levels of CXCL10, were treated with GSK126 (2μM) for 24 h followed by evaluation of CXCL10 mRNA expression and H3K27me3 by western blot analysis. Treatment of DSCs with GSK126 decreased H3K27me3 modification, as determined by western blot analysis (Fig. 6A) ; and, interestingly, correlated to enhanced CXCL10 mRNA expression (5-fold) ( Fig. 6B ). We then determined whether hCG effect on H3K27me3 could be mediated through the regulation of EZH2 expression. Thus, HESCs were treated with hCG and EZH2 mRNA expression was determined by qPCR. We observed that hCG treatment had a modest, but significant effect on EZH2 mRNA expression (1.5-fold increase) ( Fig. 6C ). These findings further suggest an epigenetic regulation of CXCL10 expression in endometrial stromal cells.
Specific Binding of H3K27me3 to the CXCL10 promoter in human decidual tissues. So far, we demonstrated in vitro, using cell lines, that hCG treatment affected H3K27me3 modification levels and correlates with CXCL10 mRNA and protein expression. Our next objective was to determine whether these findings are also present in freshly collected decidual tissue that has not undergone any in vitro manipulation. The main justification to use the whole decidual tissue is to avoid the potential non-specific effect of cell isolation and cell culture. Thus, decidual samples were obtained from term, non-labored, uncomplicated pregnancies undergoing scheduled cesarean delivery. Using these freshly collected decidual samples we then evaluated whether H3K27me3 www.nature.com/scientificreports www.nature.com/scientificreports/ modification is present in the tissues and if is responsible for the suppression of CXCL10 gene expression. First, we determined the enrichment of this histone mark on the CXCL10 promoter by performing chromatin immunoprecipitation using an anti-H3K27me3 antibody on freshly collected decidual tissue. After immune precipitation www.nature.com/scientificreports www.nature.com/scientificreports/ with the anti-H3K27me3 antibody we evaluated the enrichment of the histone mark in the CXCL10 promoter by using eight pairs of primers designed to span the 1000 bp upstream of the human CXCL10 gene. In human term uncomplicated non-labor decidua, we observed enrichment of H3K27me3 in Region 4 (505-601 base pairs upstream) of the human CXCL10 promoter (Fig. 7A,B ). There was no appreciable enrichment in regions 1-3, or 5-8 (Fig. 7A,B) . These findings were validated and quantified in six human decidua specimens (Fig. 7C,D) . Only in region 4 we are able to obtain quantitative enrichment of H3K27me3 in the CXCL10 promoter ( Fig. 7D) . Figure 7C shows a representative DNA gel of the PCR product after chromatin immunoprecipitation demonstrating enrichment of the H3K27me3 to Region 4 of the CXCL10 promoter in human decidua samples. The presence of the H3K27me3 mark at region 4 of the CXCL10 promoter correlates with low levels of CXCL10 mRNA expression in decidual tissue compared to stromal cells (Fig. 7E ). Stroma cells are used as positive control for CXCL10 expression.
hCG regulates the Binding of H3K27me3 to the CXCL10 promoter in human stromal cells. Having identified Region 4 as the site for H3K27me3 modification at the CXCL10 promoter in decidual tissues, our next objective was to determine whether hCG could promote this modification. Accordingly, we treated HESCs, expressing high levels of CXCL10, with hCG (100 IU/ml) for 2 h, followed by chromatin immunoprecipitation and PCR for enrichment of H3K27me3 mark at the CXCL10 promoter. Our data showed a 15-fold increased enrichment of H3K27me3 modification at Region 4 of the CXCL10 promoter in HESCs treated with hCG compared to non-treated cells (Fig. 8A ). Similar as reported with decidual tissues (Fig. 7) , no modifications were found in the other regions; confirming the specificity for region 4 of the CXCL10 promoter.
We then compared whether similar effect is observed during the in vitro process of differentiation into decidual cells. Thus, HESC were exposed to estrogen, cAMP and progesterone for 5 days in order to induce decidualization, followed by chromatin immunoprecipitation and PCR for enrichment of the H3K27me3 mark at the CXCL10 promoter. As shown in Fig. 8B , we confirmed that the process of differentiation from HESCs to DSCs is associated with the enrichment of the histone mark to region 4 of the CXCL10 promoter (42-fold increase; p < 0.01) (Fig. 8B) . No changes were observed in the other regions (Fig. 7B,D) .
Bacterial Lipopolysaccharide (LPS) inhibits H3K27me3 modification and induces CXCL10
expression in term human decidual tissue through the histone demethylase JMJD3. Our next objective was to determine the potential signals that could disrupt the regulation of CXCL10 expression by decidual cells. Since bacterial infections are a major cause of pregnancy complications and are able to induce and inflammatory process at the maternal/fetal interface including the expression of inflammatory cytokines/ chemokines such as CXCL10 58 , we hypothesized that bacterial signals could induce CXCL10 expression by modifying the H3K27me3 mark and consequently promote the recruitment of maternal CD8 + T cells. To test this hypothesis, first we used the organ culture model of normal human term decidual tissue obtained from non-labored cesarean deliveries which, as described above, express low levels of CXCL10 and express high levels of the H3K27me3 mark at Region 4 of the CXCL10 promoter. Thus, decidual tissues were exposed to PBS (Control) or lipopolysaccharide (LPS, 100 ng/mL) for 24 h and evaluated for the presence of H3K27me3 mark at region 4 of the CXCL10 promoter by chromatin immunoprecipitation using the anti-H3K27me3 antibody. In addition, we determined the expression of CXCL10 mRNA and protein by qPCR and Luminex assay, respectively. Decidual tissue samples exposed to control PBS showed strong enrichment of the H3K27me3 mark at Region 4 of the CXCL10 promoter ( Fig. 9A ), which correlates with low levels of CXCL10 mRNA and protein expression www.nature.com/scientificreports www.nature.com/scientificreports/ ( Fig. 9C,D) . That was not the case for the decidual samples treated with LPS where we observed a decrease of the H3K27me3 mark at Region 4 of the CXCL10 promoter ( Fig. 9A ). Using ChIP qPCR we quantified the level of enrichment for H3K27me3 in Region 4 of CXCL10 promoter and confirmed the decrease of the H3K27me3 mark following LPS treatment compared to the control vehicle ( Fig. 9B) . Changes in the presence of H3K27me3 modification at the CXCL10 promoter correlated with the expression levels of CXCL10. Indeed, our data showed that LPS treatment, by decreasing the presence of H3K27me3 modification prompted increase on CXCL10 expression at the mRNA (Fig. 9C ) and protein level (Fig. 9D ). We observed a 10-fold increase in CXCL10 mRNA expression in the LPS treated group compared to the control vehicle ( Fig. 9C) . Similarly, at the protein level we observed a significant increase in the concentration of secreted CXCL10 in the LPS treated group (32,832.56 ± 1, 902.12 pg/ mL) compared to control no treatment (13,886,86 ± 1,254.27 pg/mL*p < 0.05) (Fig. 9D) . These findings further demonstrate that the H3K27me3 modification is present in human decidual tissue, regulating CXCL10 expression and can be modified by signals induced by bacterial products such as LPS.
Next, we evaluated the mechanism how LPS decreases the H3K27me3 mark at Region 4 of the CXCL10 promoter. We screened for changes in the expression of known H3K27me3 histone demethylases such as KDM6A and JMJD3 59 in response to LPS treatment and found that the mRNA expression of JMJD3, a histone demethylase specific to the methylated histone H3K27me3, was affected by LPS treatment. Thus, when decidual organ cultures were exposed to PBS (Control) or LPS (100 ng/mL) for 24 h and evaluated JMJD3 mRNA expression, decidual organ cultures exposed to LPS showed a 3-fold increase in JMJD3 mRNA expression compared to the PBS control (p < 0.05) (Fig. 10A) . The increase in JMJD3 expression correlated with LPS-induced decrease of H3K27me3 modification from the CXCL10 promoter ( Fig. 9A,B ) and increased CXCL10 mRNA expression and protein secretion (Fig. 9C,D) .
To further confirm the role of JMJD3, we treated the decidual organ cultures with GSK-J4, a specific JMJD3 inhibitor, in the presence or absence of LPS and then examined CXCL10 expression levels. As shown in Fig. 10B , pre-treatment of decidual organ cultures with the GSK-J4 reversed the effect of LPS on CXCL10 mRNA expression. While LPS treatment induced a 19-fold increased on CXCL10 mRNA expression, the presence of GSK-J4 significantly reduced LPS-induced CXCL10 mRNA expression ( Fig. 10B; p < 0.05) . GSK-J4 treatment alone did not affect CXCL10 mRNA expression ( Fig. 10B) . This data demonstrates that infection can induce a strong and quick inflammatory response by decreasing the H3K27me3 modification through the induction of the expression of the histone demethylase JMJD3. Inverse correlation between hCG and CXCL10 levels in early pregnancy. So far as we have described in vitro, there is an inverse correlation between hCG and CXCL10 expression. Since CXCL10 expression levels has been shown to be higher during human embryo implantation 64 and subsequently decreased throughout the pregnancy 65 , we explored whether we could detect and determine in the serum of pregnant women a potential correlation between circulating hCG and CXCL-10 in the first 8 weeks of pregnancy, a period when hCG production increases as result of successful placentation. Although circulating cytokines can be affected by multiple processes taking place in the body, it is the only non-invasive source for evaluating some of the changes occurring during pregnancy 66 . To achieve this objective, we recruited an IVF cohort where we were able to monitor the day of implantation and collect samples from the earliest stages of pregnancy (between 3 and 6 weeks of gestation) and measured hCG and CXCL10 in the serum of these pregnant women throughout the first trimester of pregnancy. We detected CXCL10 in the serum of pregnant women as early as 9 days after embryo transfer and it serum levels remained constant during the subsequent days (SFig. 3). Circulating hCG levels gradually increased as pregnancy progresses (Fig. 11A) ; interestingly, when we look at the ratio between CXCL10 and hCG we observed an inverse correlation as the pregnancy progressed (Fig. 11B ). This is a noteworthy association since CXCL10 is known to be high during implantation and then silenced to prevent the recruitment of T cells 64 . 
Discussion
In this study, we describe the epigenetic role of hCG in the regulation of CXCL10 in the human decidua. We report for the first time, the identification of a specific site for the repressive histone mark H3K27me3 in the promoter of the human CXCL10gene (Region 4, 505-601 kb upstream). Furthermore, we describe the role of hCG as a regulator of CXCL10 expression by controlling the H3K27me3 mark through the expression of the histone methyltransferase, EZH2. We show that this mark can then be modified by bacterial products leading to an increase in CXCL10 expression and enhancement of the recruitment of pro-inflammatory CD8 + T cells. The modification of H3K27me3 mark is mediated by JMJD3, a histone demethylase. Our studies show an active epigenetic crosstalk between the trophoblast and decidua that results in chemokine suppression. These findings are relevant because they describe a novel mechanism of fetal-maternal anti-inflammatory regulation that can be disrupted during infection, potentially leading to inflammation and preterm birth.
One important issue to recognize is that not all inflammation in pregnancy is detrimental. The correct timing of inflammation is essential to a healthy pregnancy. For example, it is well established that implantation in the first trimester is a pro-inflammatory event [67] [68] [69] [70] [71] as is labor at the end of the third trimester [72] [73] [74] [75] . On the other hand, the second trimester of pregnancy is characterized by an anti-inflammatory profile 31, 76 . In pathological states, shifts towards a pro-inflammatory profile before term are associated with preterm birth [77] [78] [79] [80] [81] [82] [83] . Therefore, tight regulatory control of inflammation between the fetus/trophoblast unit and the decidua is critical in preventing preterm birth.
CXCL10 (IP-10) is a 77 amino acid, 10kDA protein that belongs to the CXC family of chemokines 84 , and has been shown to have pleiotropic biological activities 23 . CXCL10 is the most potent chemoattractant for cytotoxic CD8 + T cells 85 and elevated levels of CXCL10 in maternal serum, amniotic fluid, and neonatal cord blood have been associated with infection and preterm birth 21, [86] [87] [88] . In the mouse, it was described ex vivo that the promoter region of the chemokines CXCL9 and CXCLl10 revealed elevated levels of the repressive histone mark H3K27me3 in DSCs versus myometrial cells, which was then confirmed in vivo 26 . Methylation of histone 3 at Lysine 27 (K27) is one of the most well-described epigenetic modifications. When H3K27 is trimethylated to H3K27me3, it is tightly associated with its target gene promoter, inactivating the promoter, and consequently shutting down target gene transcription 50, 56, 57 . These findings suggest that epigenetic modifications of stromal/decidual cells are critical regulators of these chemokines and consequently of the immune regulation at the maternal fetal interface.
CXCL10 is a potent pro-inflammatory chemokine whose regulation appears to be important during pregnancy. Human cohort studies have shown that not only does CXCL10 expression increase with normal term labor (as do other inflammatory cytokines), but importantly, elevated levels of CXCL10 are associated with preterm birth and chorioamnionitis, suggesting that CXCL10 suppression in the decidua is necessary for the normal course of pregnancy 21, 87, 89 . Recently, the notion of a decidual clock has been proposed, wherein "timing of labor" is dependent on the suppression and release of certain elements at the correct timepoint during pregnancy. In the beginning of pregnancy, suppressive factors function to maintain the pregnancy and prevent miscarriage. The Figure 11 . hCG and CXCL10 expression ratio throughout early gestation. Circulating levels of hCG and CXCL10 were measured using ELLA assay in serum samples collected from normal pregnant women during the first 4 weeks of pregnancy. (A) hCG is detected in the serum as early as 9 days after embryo transfer and shows a steady increase in the following days. (B) Ratios of CXCL10 and hCG across gestational age were determined in blood samples collected from IVF pregnancies. The line represents the mean estimation by LOWESS and the colored areas the 95% confidence intervals of the mean estimation. CXCL10:hCG ratios decreased in normal pregnancies in relation to gestational age.
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www.nature.com/scientificreports www.nature.com/scientificreports/ suppression is then released at the end of pregnancy and allows labor to occur 90 . Our data support this theory of the decidual clock by describing the regulation of CXCL10 in the decidua. By secreting hCG in the beginning of the pregnancy, the fetal/placental unit works to "set the timing" on the decidual clock, to suppress inflammatory mediators such as CXCL-10. Based on our data, we propose that hCG is the fetal anti-inflammatory factor of pregnancy ( Fig. 12 ).
Our data support hCG's anti-inflammatory and tolerance-promoting functions. Human chorionic gonadotropin, a factor secreted by the trophoblast, has already known immunological properties: It promotes the induction and activation of regulatory T cells, and these cells are necessary for the successful establishment of pregnancy 33, 34 . hCG treatment of dendritic cells prior to conception induces regulatory T cell expansion and leads to decreased spontaneous abortion in mice 35 . In addition, hCG stimulates macrophage function and activation 91, 92 . In our study, hCG and its downstream messenger cyclic AMP-treatments both suppress CXCL10 expression and secretion in stromal cells. CXCL10 suppression supports the anti-inflammatory function of hCG. CXCL10 suppression also results in decreased CD8 + T cell migration in decidual cells compared to stromal cells. This data is in line with others who have found that hCG down-regulates CD8 + T cells in pregnancy 93 . Furthermore, hCG suppresses not only CXCL-10, but other pro-inflammatory cytokines as well, such as GRO-alpha, IL-8, IL-17, and RANTES. Kokdehoff and others also found that hCG decreases inflammatory cytokines in women treated with hCG prior to IVF 94 . However, our data go beyond mere description, and we characterize the mechanism by which the fetal factor hCG suppresses CXCL10 expression in decidual cells as it may promote maternal tolerance.
We describe how the fetus/placental unit is an active participant in the process of fetal-maternal tolerance: It acts through hCG using epigenetic mechanisms to suppress inflammation. Our data illustrate a novel role of hCG as a functional epigenetic regulator suppressing inflammation. Treatment of stromal cells with hCG upregulates EZH2, a specific histone methyltransferase, enriching the repressive histone mark H3K27me3 in Region 4 of the CXCL10 promoter. This enrichment results in decreased expression and secretion of CXCL-10. In addition, enrichment of the H3K27me3 (and subsequent suppression of CXCL-10) also occurred during decidualization with cyclic AMP. This data supports a role of hCG in maintaining the normal state of pregnancy.
We also show how infection can induce inflammation and break the fetal-maternal tolerance by disrupting the epigenetic mechanism. In our organ culture experiments using term uncomplicated human samples, we are able to induce CXCL10 expression and secretion with LPS treatment. Moreover, we show that LPS treatment decreases the enrichment of H3K27me3 in Region 4 of the CXCL10 promoter. LPS affects H3K27me3 methylation by inducing JMJD3, a histone demethylase, which is also seen in the regulation of other pro-inflammatory cytokines in HUVEC cells 95 .
In conclusion, our data demonstrates how the fetus/trophoblast unit actively participates in regulating inflammation at the maternal-fetal interface in order to promote pregnancy. The epigenetic inhibition of CXCL10mediated inflammation is promoted by hCG on stromal cells. However, in cases of infection, LPS can modulate the suppression, and induce inflammatory chemokines that will recruit cytotoxic T cells to the maternal-fetal interface. Our results provide a possible mechanism by which infection can induce pregnancy complications such as preterm birth (Fig. 12) .
As an anti-inflammatory agent, hCG may have therapeutic potential for prevention of miscarriage and preterm birth in pregnancies complicated by infection. Further clinical trials are needed to investigate the therapeutic role of hCG for prevention of fetal loss.
Materials and Methods
All methods were performed in accordance with the relevant guidelines and regulations and approved by Yale University. Reagents and cell line. Reagents and cell line used in the experiments were as follows: LPS isolated from E. coli 0111:B4 (Sigma-Aldrich, St. Louis, MO), GSK-J4 and GSK126 were purchased from (ApexBio, Houston, TX) and telomerase-immortalized human endometrial stromal cells (HESC) were developed in our laboratory and previously reported 52, 96 . Patient recruitment and sample collection. The description of the patients population, recruitment and characteristics has been previously described 98 as following:
IVF Cohort. Recruitment of IVF patients and storage of samples was approved by the Yale institutional Review Board (IRB) with no written consent requirement (#2000021607). All the participants had an informed consent for study participation. An aliquot of blood was assigned for the study during the regular blood test for monitoring chemical pregnancy (hCG serum levels). The study was deemed to have minimal harm to patients so only verbal consent was requested. The investigators have no access to any personal information. Coded serum samples were provided to the investigators without any patient information.
Patients aged 18-44 undergoing fresh or frozen day 3 or day 5 (blastocyst) embryo transfer from October 2017 to July 2018 were eligible for participation. Exclusion criteria were patients with chronic autoimmune disease (such as lupus, thyroid antibodies, ulcerative colitis, or Crohn's disease), diabetes and hypertension requiring medication, endometriosis confirmed by laparoscopy, or current illness (in general, we excluded patients with an underlying inflammatory process). We also excluded patients with prior pregnancy losses, unless the tissue from the loss had undergone genetic testing and was determined to be chromosomally abnormal. Patients were asked to participate at the time of embryo transfer. Blood was collected by venipuncture into 10 mL vacutainer tubes starting at the time of the first positive β-hCG, 8-12 days after embryo transfer and then every 48 hours until an intrauterine pregnancy was confirmed using transvaginal ultrasound, or when a pregnancy was deemed as biochemical based on declining β-hCG levels following an initial positive test. Samples were left at room temperature for 60 minutes to allow for clotting and then centrifuged (Thermo Scientific Sorvall ST 16, Waltham, MA) at 3,000 RPM for ten minutes at room temperature. Serum was aliquoted into 1.5 mL polypropylene RNase-and DNase-free microcentrifuge tubes and stored in −80 °C freezers until ready for testing.
Statistical analysis.
Statistical analyses was done using the Statistical Package for Social Science (SPSS) for windows and GraphPad Prism software, version 5. Differences between two groups were analyzed using Student's t-test. The differences between multiple groups were analyzed by one-way ANOVA and Chi-square test. P-values less than 0.05 were considered significant. All the experiments were done in triplicate and a minimum of three independent experiments.
